Related Experiment Video
Updated: Feb 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Stroke prevention in atrial fibrillation – latest guideline recommendations and real world data
Insights
Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in atrial fibrillation (AF). Real-world data confirm NOACs are safe and effective, with specific antidotes becoming available.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation (AF) affects 1% of the general population, rising to 8% in those over 80.
- AF increases risks of palpitations, tachycardia, heart failure hospitalizations, and stroke.
- Oral anticoagulation is crucial for stroke prevention in AF patients.
Purpose of the Study:
- To review current guidelines and evidence regarding anticoagulation in atrial fibrillation.
- To highlight the advantages of non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists.
- To discuss the safety, feasibility, and antidote availability for NOACs.
Main Methods:
- Review of 2016 guidelines for atrial fibrillation management.
- Analysis of randomized controlled trials and real-world data on NOACs.
- Examination of contraindications and antidote developments for NOACs.
Main Results:
- Non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over vitamin K antagonists due to reduced bleeding risk, particularly intracranial hemorrhage.
- Real-world data support the safety and feasibility of NOAC use in atrial fibrillation.
- Antiplatelet therapy is no longer indicated for stroke prevention in AF.
- NOACs are contraindicated in patients with mechanical valve replacement and valvular atrial fibrillation.
Conclusions:
- NOACs represent a preferred and effective strategy for stroke prevention in atrial fibrillation.
- The availability of specific antidotes enhances the safety profile of NOACs.
- Ongoing research and real-world evidence continue to support the role of NOACs in AF management.
Abstract:
Atrial fibrillation (AF) occurs with a prevalence of 1 % in the general population, up to 8 % in patients over 80 years of age and can lead to palpitations, tachycardia, hospitalization for heart failure and stroke. In order to prevent strokes, oral anticoagulation is necessary. In the 2016 guidelines for the management of atrial fibrillation, non vitamin K anticoagulants (NOACs) are preferred among vitamin K anticoagulants due to less severe bleeding, especially intracranial haemorrhage. There is also no longer evidence for antiplatelet therapy in AF. Apart from randomized controlled trials it has been shown in real world data that use of NOACs is safe and feasible. NOACs are not indicated in patients with mechanical valve replacement and valvular atrial fibrillation. Since November 2015 the first specific antidote for dabigatran is available in Germany, a factor Xa antidote (apixaban, rivaroxaban, edoxaban) is being tested in a phase III study.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Guidelines for Nursing Documentation I
Factual:
The following points emphasize the significance of upholding accurate and unbiased documentation in healthcare.
Guidelines for Sketching a Curve

